Xin Lang Cai Jing·2026-03-05 03:47Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company based in Yantai, Shandong, China, established on July 4, 2008, and listed on March 31, 2022 [1] - The company focuses on the development and commercialization of therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [1] - The main revenue sources are from product sales (99.46%), material sales (0.38%), and leasing services (0.16%) [1] Stock Performance - On March 5, Rongchang Biopharmaceuticals' stock rose by 5.04%, reaching a price of 93.16 CNY per share, with a trading volume of 252 million CNY and a turnover rate of 1.70%, resulting in a total market capitalization of 52.587 billion CNY [1] Fund Holdings - Penghua Fund has a significant holding in Rongchang Biopharmaceuticals, with its Penghua SSE STAR Market Biomedicine ETF (588250) increasing its position by 7,625 shares in the fourth quarter, totaling 76,900 shares, which represents 2.85% of the fund's net value [2] - The ETF has a current size of 210 million CNY and has experienced a year-to-date loss of 7.09%, ranking 5242 out of 5570 in its category [2] Fund Management - The fund manager of the Penghua SSE STAR Market Biomedicine ETF is Lin Song, who has been in the position for 2 years and 250 days, managing total assets of 3.741 billion CNY [3] - During Lin Song's tenure, the best fund return was 43.89%, while the worst return was -22.7% [3]